Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2015

View Archived Issues

Pacific Therapeutics launches share offer

Cell Cure initiates phase I/II study of OpRegen in patients with dry AMD and geographic atrophy

Institut Pasteur Korea and Qurient report anti-TB compounds

Vaxin to acquire Immune Targeting Systems

Merck KGaA discloses new BTK inhibitors

Novartis reports SMN expression enhancers

Amarantus enters into Alzheimer's biomarker collaboration with Anavex Life Sciences

Servier and Vernalis patent novel Bcl-2 inhibitors

Metabolic Solutions Development divulges PPAR-sparing compounds

Neutrophil activation shows potential as a biomarker for ischemia and inflammation

Actavis proposes adopting Allergan as corporate name

Revlimid approved in E.U. for previously untreated multiple myeloma

MMP-12 knockdown protects BBB integrity and reduces permeability

Teva to study TV-45070 for post-herpetic neuralgia in phase IIb trial

Novel anti-HIV agent shows potential as HIV vaccine alternative

Summit initiates phase Ib modified diet trial of SMT-C1100 for Duchenne muscular dystrophy

BioNovion and Genmab establish immune oncology collaboration

Clinical milestone achieved in development of rVSV-EBOV Ebola vaccine candidate

Tambocor fine granules approved in Japan for pediatric patients

Midatech Pharma reports preclinical data on OpsiSporin sustained-release treatment for uveitis

Iconic Therapeutics starts phase II trial of hI-con1 in choroidal neovascularization

Specific inhibition of NLRP3 shows potential for the treatment of inflammatory diseases

Pfizer presents RORC2 inhibitors

New HIV protease inhibitors disclosed by Merck & Co.

CEPT inhibitors designed at Merck & Co.